{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:53:03Z","timestamp":1787629983954,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.semnephrol.2024.151500","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:58:29Z","timestamp":1711547909000},"page":"151500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitors in Recipients of Renal Allografts"],"prefix":"10.1016","volume":"44","author":[{"given":"Karthik","family":"Venkataraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5256","key":"10.1016\/j.semnephrol.2024.151500_bib0001","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151500_bib0002","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.semnephrol.2024.151500_bib0003","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.3748\/wjg.v25.i29.3920","article-title":"Immunotherapy in colorectal cancer: available clinical evidence, challenges and novel approaches","volume":"25","author":"Tintelnot","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"10088","key":"10.1016\/j.semnephrol.2024.151500_bib0004","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.semnephrol.2024.151500_bib0005","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2024.151500_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000461","article-title":"Fujimoto N. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma","volume":"8","author":"Hotta","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.semnephrol.2024.151500_bib0007","unstructured":"Drug Approval Package: Yervoy (ipilimumab) Injection NDA #125377\". U.S. Food and Drug Administration (FDA). 25. 2 October 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125377Orig1s000TOC.cfm. Accessed March 20, 2024."},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151500_bib0008","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151500_bib0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151500_bib0010","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ckj\/sfad109","article-title":"Immune checkpoint inhibitors and their interaction with proton pump inhibitors\u2013related interstitial nephritis","volume":"16","author":"Miao","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360."},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151500_bib0012","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience","volume":"14","author":"Oleas","year":"2021","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151500_bib0013","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151500_bib0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"Oncologist"},{"issue":"4961","key":"10.1016\/j.semnephrol.2024.151500_bib0016","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.2113314","article-title":"A cell culture model for T lymphocyte clonal anergy","volume":"248","author":"Schwartz","year":"1990","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151500_bib0017","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151500_bib0018","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151500_bib0019","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J Immunol"},{"issue":"suppl","key":"10.1016\/j.semnephrol.2024.151500_bib0020","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"},{"issue":"7528","key":"10.1016\/j.semnephrol.2024.151500_bib0021","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.semnephrol.2024.151500_bib0022","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151500_bib0023","doi-asserted-by":"crossref","first-page":"9669","DOI":"10.18632\/oncotarget.3430","article-title":"Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype","volume":"6","author":"Amend","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151500_bib0024","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"issue":"suppl 7","key":"10.1016\/j.semnephrol.2024.151500_bib0025","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"5238","key":"10.1016\/j.semnephrol.2024.151500_bib0026","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151500_bib0027","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151500_bib0028","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicited by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151500_bib0029","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0031","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-023-37230-4","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy","volume":"14","author":"Dunlap","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151500_bib0032","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/ki.2013.458","article-title":"Malignancy-related mortality following kidney transplantation is common","volume":"85","author":"Farrugia","year":"2014","journal-title":"Kidney Int"},{"issue":"23","key":"10.1016\/j.semnephrol.2024.151500_bib0033","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.semnephrol.2024.151500_bib0034","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.semnephrol.2024.151500_bib0035","doi-asserted-by":"crossref","first-page":"15375","DOI":"10.18632\/oncotarget.23841","article-title":"Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"issue":"9218","key":"10.1016\/j.semnephrol.2024.151500_bib0036","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(00)02298-4","article-title":"Cancer risk in patients on dialysis and after renal transplantation","volume":"355","author":"Birkeland","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0037","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12957-023-02892-3","article-title":"Tumors after kidney transplantation: a population study","volume":"21","author":"Ietto","year":"2023","journal-title":"World J Surg Oncol"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151500_bib0038","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1111\/ajt.14289","article-title":"Incidence and predictors of cancer following kidney transplantation in childhood","volume":"17","author":"Francis","year":"2017","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151500_bib0039","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","article-title":"Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients","volume":"7","author":"Webster","year":"2007","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0040","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2005.07021.x","article-title":"A population-based study of skin cancer incidence and prevalence in renal transplant recipients","volume":"154","author":"Moloney","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151500_bib0041","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaad.2012.09.030","article-title":"Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation","volume":"68","author":"Gogia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151500_bib0042","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.semnephrol.2024.151500_bib0043","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2024.151500_bib0044","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2021.01.005","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study","volume":"147","author":"Espi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal-change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0046","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151500_bib0047","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal complications of immune checkpoint blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0048","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"21","key":"10.1016\/j.semnephrol.2024.151500_bib0049","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/imt-2021-0195","article-title":"Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review","volume":"14","author":"Rossi","year":"2022","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151500_bib0051","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0052","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151500_bib0053","doi-asserted-by":"crossref","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151500_bib0054","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","article-title":"Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue","volume":"24","author":"Aguirre","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0056","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.semnephrol.2024.151500_bib0057","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2022.40.16_suppl.9507","article-title":"Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +\/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers","volume":"40","author":"Schenk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.semnephrol.2024.151500_bib0058","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1200\/JCO.2023.41.16_suppl.9519","article-title":"Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1","volume":"41","author":"Hanna","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0059","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151500_bib0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151500_bib0061","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.11991019","article-title":"Evaluation and treatment of acute rejection in kidney allografts","volume":"15","author":"Cooper","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151500_bib0062","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1470-2045(22)00395-3","article-title":"Managing immune checkpoint inhibition in transplant recipients","volume":"23","author":"Lebb\u00e9","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0063","doi-asserted-by":"crossref","first-page":"ltac012","DOI":"10.1093\/immadv\/ltac012","article-title":"Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?","volume":"2","author":"Katsumoto","year":"2022","journal-title":"Immunother Adv"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151500_bib0064","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1111\/trf.17114","article-title":"Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: a review","volume":"62","author":"Onwuemene","year":"2022","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151500_bib0065","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2016091034","article-title":"Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-Free DNA and Active Rejection in Kidney Allografts","volume":"28","author":"Bloom","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151500_bib0066","first-page":"53","article-title":"Urinary CXCL9 and CXCL10 levels and acute renal graft rejection","volume":"10","author":"Ciftci","year":"2019","journal-title":"Int J Organ Transplant Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151500_bib0067","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/ajt.12426","article-title":"Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury","volume":"13","author":"Hricik","year":"2013","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151500_bib0068","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001620","article-title":"Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy","volume":"8","author":"Abed","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.semnephrol.2024.151500_bib0069","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-20-4314","article-title":"Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms","volume":"27","author":"Abbott","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151500_bib0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151500_bib0071","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(21)00582-9","article-title":"HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study","volume":"23","author":"Naranbhai","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:51:19Z","timestamp":1748357479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929524000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0270929524000172"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151500","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors in Recipients of Renal Allografts","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151500"}}